PATENT CLAIM ANALYSIS

Application Number: 16081550
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["514", "007200"]

Abstract:
The present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.

Claim (Index 14):
A method for reducing or delaying the development of diabetic foot ulcer, comprising administering liraglutide in a therapeutically effective amount to a subject in need thereof, wherein the subject has type 2 diabetes and one or more risk factors of vascular disease selected from the group consisting of microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction, and ankle/brachial index <0.9.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 96.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15401651', '15616974', '15354053', '14918713', '13295174']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6764913734361238
- 35 USC 102 Novelty (BERT): 0.496311980928789
- Combined Prediction Score: 0.6584734341853903
- Mean Citation Score: 181.929686
- Max Citation Score: 257.79913
- Similarity Product: 206.30333730174303

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test